No abstract

Synthesis of some new N-{5- [(1H-benzo[d]imidazol-1-yl)methyl]isoxazol-3-yl}benzamide hybrids is presented herein. The in vitro anti-cancer activity of the synthesized compounds against four human cancer cell lines A549 (lung), HeLa (cervical), IMR-32 (neuroblast), and HEK-293 (embryonic kidney) has been tested. Four products have been determined to be active against all the cell lines. The compound N- {5-[(1H-benzo[d]imidazol-1-yl)methyl]isoxazol-3-yl}-3,5-dimethoxybenzamide has been characterized by significant anti-proliferative efficiency towards all tested cancer cells compared to the standard.